Main navigation
Search Results
-
Funding Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 21/02/2023https://www.gesundheitsindustrie-bw.de/en/database/funding/eu4health-programme-eu4h-action-grants-2022 -
Funding EU4Health Programme (EU4H) – Action Grants 2022
Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 21/02/2023https://www.bio-pro.de/en/service/funding/eu4health-programme-eu4h-action-grants-2022 -
Concentrated Specialist Knowledge https://www.bio-pro.de/en/projectsProjects
-
Dossier - 06/03/2018 Big data - the big promise of the new digitised world
Big data is a widely used buzzword in today's information era. The use of big data in the digital world presents both an opportunity and a risk. Mass data is now used and analysed in almost all areas of life. Even the healthcare sector is undergoing extensive digitisation.
https://www.gesundheitsindustrie-bw.de/en/article/dossier/big-data-the-big-promise-of-the-new-digitised-world -
Press release - 28/08/2023 Innovative computational approach helps design proteins for cancer treatment
The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-computational-approach-helps-design-proteins-cancer-treatment -
Press release - 21/09/2023 Mutation-specific peptide vaccine against midline gliomas used in patients for the first time
Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-specific-peptide-vaccine-against-midline-gliomas-used-patients-first-time -
Press release - 19/09/2023 Better distinguish chronic inflammation and cancer of the pancreas
Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/chronische-entzuendung-und-krebs-der-bauchspeicheldruese-praeziser-unterscheiden -
Press release - 10/08/2023 Computer-aided cell analysis for faster diagnosis of blood diseases
Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples. The algorithm can help physicians diagnose blood disorders and is available as an open source method for research purposes.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/computergestuetzte-zellanalyse-fuer-die-schnellere-diagnose-von-blutkrankheiten -
Dossier - 11/10/2023 The quantum revolution in the healthcare industry
From ultra-fast quantum computers to highly sensitive sensors - quantum technologies could take medicine a giant step forward. Possible areas of application range from drug development and early cancer detection to reading brain waves to control prostheses or exoskeletons. The German state of Baden-Württemberg plays a key role in the development of sensors in particular.
https://www.gesundheitsindustrie-bw.de/en/article/dossier/The-quantum-revolution-in-the-healthcare-industry -
Nanoparticles as drug carriers - 09/11/2023 Inhalation of nanocarriers for antibiotics against resistant tuberculosis pathogens
Around ten million people worldwide still contract tuberculosis every year. With an estimated 1.4 million deaths a year, tuberculosis was the world’s deadliest infectious disease until COVID-19. The high mortality rate is down to the sophisticated biology of the pathogen Mycobacterium tuberculosis. A team of researchers from the KIT and the Research Centre Borstel (FZB) has developed a method that aims to outsmart the bacterium once and for all.
https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-nanocarriers-antibiotics-against-resistant-tuberculosis-pathogens -
Press release - 18/08/2023 TÜV SÜD gets UK Approved Body designation
TÜV SÜD has received approval as a UK Approved Body (UKAB) for medical devices. With this approval, medical device manufacturers can implement UKCA certification for the UK market and CE certification for the European market in a time- and cost-efficient manner with TÜV SÜD.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/tuev-sued-gets-uk-approved-body-designation -
Augmented reality for visual orientation - 15/11/2023 Fall prevention with the help of balance-enhancing AR glasses
As we age, our eyesight deteriorates and we have increasing difficulties with orientation. This can lead to balance problems and fatal falls. A team led by Dr. Lorenz Assländer from the University of Konstanz is currently developing a prototype of augmented reality (AR) glasses that use superimposed patterns to facilitate visual orientation in space, thereby helping to improve balance control and prevent falls.
https://www.gesundheitsindustrie-bw.de/en/article/news/fall-prevention-help-balance-enhancing-ar-glasses -
High-resolution microscopy technology bypassing the diffraction limit - 26/10/2023 From micro- to nanoscope
It has long been impossible to distinguish objects closer than 200 nanometres using light microscopes. However, novel devices developed by a company called abberior Instruments GmbH, which use technology developed by Nobel Prize winner Prof. Dr. Stefan Hell and his teams in Heidelberg and Göttingen, are now able to bypass this resolution limit and provide detailed insights into living cells in the lower nanometre range.
https://www.gesundheitsindustrie-bw.de/en/article/news/micro-nanoscope -
-
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy
Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetisch-wirkende-medikamente-koennten-krebs-immuntherapie-unterstuetzen -
Press release - 18/10/2023 SARS-CoV-2: Alert immune system in the respiratory tract protects children from severe courses of the disease
Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-aktiveres-immunsystem-den-atemwegen-schuetzt-kinder-vor-schweren-verlaeufen -
Press release - 02/10/2023 Distributed artificial intelligence to improve patient care in the operating room
A research team of scientists from the Fraunhofer IPA, the Bosch Digital Innovation Hub at Bosch Health Campus and the Institute of Image-Guided Surgery (IHU) of Strasbourg has jointly launched the DAIOR project. Within the framework of the project, the project partners are working on realizing the operating room of the future with help of artificial intelligence and robot assisted telemedicine.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/distributed-artificial-intelligence-improve-patient-care-operating-room -
Press release - 11/10/2023 The new Center for Bionic Intelligence Tübingen Stuttgart
The new Center for Bionic Intelligence Tübingen Stuttgart aims to optimize the interaction between humans and technical systems in a fundamentally new way. Scientists from the Universities of Stuttgart and Tübingen, the Max Planck Institute for Intelligent Systems and the Max Planck Institute for Biological Cybernetics are conducting research on intelligent bionic systems that will aid understanding and treatment of certain diseases of the CNS.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/zentrum-fuer-bionic-intelligence-tuebingen-stuttgart-gegruendet -
Press release - 25/10/2023 Epigenetically acting drugs could support cancer immunotherapy
Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy -
Press release - 20/10/2023 Why tuberculosis bacteria form long chains
A researcher team from Ecole Polytechnique Federal de Lausanne led by Dr. Vivek Thacker now group leader at the Department of Infectious Diseases at Heidelberg University Hospital have studied why tuberculosis bacteria form long strands and how this affects their infectivity. Their findings could lead to new therapies and have now been published in the journal Cell.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-tuberculosis-bacteria-form-long-chains -
Press release - 04/10/2023 Therapeutic option for tumor patients with the rare DNAJB1-PRKACA gene fusion
A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).
https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-option-tumor-patients-rare-dnajb1-prkaca-gene-fusion -
Press release - 17/10/2023 BioCopy and YUMAB announce partnership for development of innovative safeTY-engager® platform
The development of highly specific T-cell engagers directed against pHLA tumor targets will be quick and easy. BioCopy's innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. YUMAB develops highly specific antibodies with their advanced antibody technologies.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-und-yumab-verkuenden-partnerschaft-fuer-entwicklung-innovativer-safety-engager-r-plattform -
Press release - 26/10/2023 Innovative research aims to improve wound healing and cancer therapy
Jun.-Prof. Dr. Priscilla Briquez, junior professor at the Department of General and Visceral Surgery at the Freiburg University Medical Center and member of the Medical Faculty at the University of Freiburg, has received a European Research Council (ERC) Starting Grant from the European Commission. Her DRESSCODE project will receive a total of 1.5 million euros funding for five years.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-forschung-soll-wundheilung-und-krebstherapie-verbessern -
Computer-assisted genome mining - 04/12/2023 Natural product genomics opens up new avenues in the search for antibiotics
Antibiotic-resistant pathogens are increasingly endangering our health. Since most of the drugs currently in use are based on secondary metabolites produced by bacteria or fungi, the research group of Prof. Dr. Nadine Ziemert in Tübingen is developing bioinformatic tools to specifically search the genome of these organisms for previously unknown antimicrobial agents.
https://www.gesundheitsindustrie-bw.de/en/article/news/natural-product-genomics-opens-new-avenues-search-antibiotics -
Press release - 29/11/2023 EU funds research into causes and new therapies for multiple sclerosis
The progression of multiple sclerosis (MS) can usually be slowed down with medication, but a cure is currently not possible. It is now established that Epstein-Barr viruses are involved in the development of MS. However, it is not known how the pathogens trigger the disease. The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe program.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-foerdert-forschung-zu-ursachen-und-neuen-therapien-der-multiplen-sklerose -
Health Data Futures project - 11/01/2024 Creating a network of trust
In the three-nation project "Health Data Futures", stakeholders and experts from Germany, France and Switzerland have launched a series of patient-centred innovations. Using various future scenarios, the project partners may be able to come up with even more scenarios.
https://www.gesundheitsindustrie-bw.de/en/article/news/creating-network-trust -
Press release - 29/11/2023 Tracing the Evolution of the Cerebellum
Heidelberg scientists unveil genetic programmes controlling the development of cellular diversity in the cerebellum of humans and other mammals. The research results have now been published in the journal Nature.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-evolution-cerebellum -
Press release - 30/11/2023 Taking antibiotics back in time
University of Tübingen researchers reverse the evolution of a class of antibiotics to gain insights for the development of new drugs.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/taking-antibiotics-back-time -
Press release - 06/11/2023 Improving the efficacy of cancer immunotherapy with modified CAR-T cells
CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/improving-efficacy-cancer-immunotherapy-modified-car-t-cells -
Press release - 10/11/2023 Therapy resistance in multiple myeloma: molecular analyses of individual cancer cells reveal new mechanisms
All cancer cells - even those within the same tumor - differ from each other and change over the course of a cancer disease. Scientists at Heidelberg University Hospital, the Medical Faculty in Heidelberg and the German Cancer Research Center discovered molecular changes in multiple myeloma that help individual cancer cells to survive therapy.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapy-resistance-multiple-myeloma-molecular-analyses-individual-cancer-cells-reveal-new-mechanisms -
Press release - 15/11/2023 Nanoparticles for optimized cancer therapy
Pancreatic cancer is one of the deadliest types of cancers in humans. Chemotherapies attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely. The approach was developed by a research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanopartikel-fuer-optimierte-krebstherapie -
Press release - 30/10/2023 New research group: construction of tissue in laboratory
An interdisciplinary research group combining mechanical engineering and biotechnology has taken up its work at the Institute for Molecular Systems Engineering and Advanced Materials (IMSEAM) of Heidelberg University. The team under the direction of Dr Kai Melde will pursue an innovative approach to biofabrication – 3D cell culture using ultrasound. Tools are being developed that can be used as an alternative to or enhancement for 3D printing.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-forschungsgruppe-konstruktion-von-gewebe-im-labor -
All-enzyme hydrogels in action - 13/12/2023 Biocatalytic foams enable the sustainable synthesis of complex molecules
Conventional chemical synthesis processes consume large amounts of energy and environmentally harmful solvents. Prof. Dr. Christof Niemeyer’s team at the Karlsruhe Institute of Technology has generated porous, solid foams from crosslinked enzymes that allow the production of high-quality compounds under significantly more environmentally friendly conditions. The novel biocatalysts are also extremely resistant and have a long shelf life.
https://www.gesundheitsindustrie-bw.de/en/article/news/biocatalytic-foams-enable-sustainable-synthesis-complex-molecules -
Press release - 18/12/2023 Researchers discover novel antibiotic substance from the human nose
For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-discover-novel-antibiotic-substance-human-nose -
Press release - 08/12/2023 Where does chronic pain come from?
Professor Dr. Rohini Kuner from the Medical Faculty of Heidelberg University receives the Leibniz Prize of the German Research Foundation (DFG).
https://www.gesundheitsindustrie-bw.de/en/article/press-release/woher-kommen-chronische-schmerzen -
Press release - 05/01/2024 How memories are formed in the brain – a new role for the internal compass
University of Tübingen neuroscientists discover new functions of head-direction cells suggesting they may contribute to episodic memory formation.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-memories-are-formed-brain-new-role-internal-compass -
Press release - 11/12/2023 Heidelberg center for personalized medicine achieves the highest quality standards
The German Cancer Society has certified the Center for Personalized Medicine (ZPM) at Heidelberg University Hospital. At the ZPM Heidelberg, patients with advanced and rare cancers and, in future, people with severe chronic inflammatory diseases will receive a molecular genetic analysis. The detailed information can open up new treatment options for those affected.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/zentrum-fuer-personalisierte-medizin-heidelberg-erfuellt-hoechste-qualitaetsstandards -
Waste recycling in the healthcare sector - 30/01/2024 Sustainability in medical technology: a particular challenge
Quality and safety of medical care are top priorities in the healthcare sector. However, this is often at the expense of climate protection, as not only are energy and raw material consumption very high, but so is the amount of waste generated due to the large number of disposable products. Sustainable product design and improved recycling strategies are therefore required to reduce waste and the CO2 footprint.
https://www.gesundheitsindustrie-bw.de/en/article/news/sustainability-medical-technology-particular-challenge -
Robotics in medicine - 15/02/2024 Copied from the pangolin: innovative flexible miniature robot for minimally invasive applications
Wireless miniature robots that can penetrate hard-to-reach areas of the body for the purpose of medical treatment are currently still a vision of the future. Researchers at the Max Planck Institute for Intelligent Systems in Stuttgart have now constructed the first flexible prototype modelled on the pangolin, which can generate heat and stop bleeding, kill tumour cells or release "cargo" in the model system.
https://www.gesundheitsindustrie-bw.de/en/article/news/copied-pangolin-innovative-flexible-miniature-robot-minimally-invasive-applications -
Event - - BIO International Convention 2024
San Diego, United States, Kongress/Symposiumhttps://www.gesundheitsindustrie-bw.de/en/event/bio-international-convention-2024 -
Event - - MedtecLIVE 2024
Stuttgart, Messehttps://www.gesundheitsindustrie-bw.de/en/event/medteclive-2024 -
-
Press release - 08/01/2024 Brain tumors in children: Cancer cells become less aggressive as they migrate within the tumor
Certain brain tumors in small children contain cells that develop very similarly to normal brain cells and others that have already developed malignantly, depending on where they are located within the tumor.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirntumoren-bei-kindern-krebszellen-werden-auf-ihrer-wanderung-im-tumor-weniger-aggressiv -
Press release - 17/01/2024 AI-based support system for skin cancer diagnostics explains its decisions
Artificial intelligence (AI) can help dermatologists to detect skin cancer. However, many dermatologists distrust the algorithms' decisions, which they cannot comprehend. Scientists at the German Cancer Research Center have now developed an AI-based support system for skin cancer diagnostics that explains its decisions.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-based-support-system-skin-cancer-diagnostics-explains-its-decisions -
Press release - 03/01/2024 Reprogrammed fat cells support tumor growth
Mutations of the tumor suppressor p53 not only have a growth-promoting effect on the cancer cells themselves, but also influence the cells in the tumor's microenvironment. Scientists at the Weizmann Institute in Israel and at the German Cancer Research Center (DKFZ) have now shown that p53-mutated mouse breast cancer cells reprogram fat cells.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-fat-cells-support-tumor-growth -
Press release - 17/01/2024 Immatics Announces Pricing of $175 Million Public Offering
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-pricing-175-dollar-million-public-offering -
Press release - 05/01/2024 Prostate cancer: Newly-developed inhibitor shows massive potential
More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential -
Press release - 04/01/2024 Key player in viral heart inflammation discovered
Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/key-player-viral-heart-inflammation-discovered -
Press release - 15/01/2024 Maturation instead of cell death: Defective signalling pathways disrupt immune cell development
Researchers at the Faculty of Medicine of the University of Freiburg discover key factor in the development of immune cells. New approaches for the treatment of ALPS.
https://www.gesundheitsindustrie-bw.de/en/article/maturation-instead-cell-death-defective-signalling-pathways-disrupt-immune-cell-development -